Michael Babich, Ph.D.
UC Davis School of Medicine, LabyRx Chief Executive Officer
Co-Founder of LabyRx and CEO since 2021, Dr. Babich brings over 35 years of experience leading clinical development and regulatory filings for multiple biopharma companies. Previously, Dr. Babich was the Co-Founder and Chief Scientific Officer of Mission Therapeutics where he was responsible for the clinical development strategy and execution of a humanized anti-cancer antibody and vaccine development, as well as a broad-scope anti-allergy treatment. He also built and sold a drug testing laboratory and research incubator when he was also an Assistant Professor of Pharmacology at the University of Illinois. Prior to biotechnology, he served as Medical Platoon Leader for the U.S. Army Medical Service Corps, and continued serving in the Reserves in key positions to include as Executive Office with oversight of the national and international operations of a large US Army Hospital. Dr. Babich has published over one hundred combined scientific papers and patents, and is the recipient of numerous education awards and research grants. He completed his postdoctoral training in the Endocrine Unit at the University of California, San Francisco, and earned his Ph.D. in Pharmacology from the University of Kentucky.
James (Jim) A. Radosevich, Ph.D.
Chief Scientific Officer
Co-Founder and Chief Scientific Officer of LabyRx, Dr. Radosecich brings nearly four decades of scientific leadership and a successful track record of early drug discovery and cancer vaccine development. Over the past 30 years, Dr. Radosevich has advised over two dozen life science companies covering all aspects of drug development, manufacturing, and clinical trials. Previously, he was a Professor and Clinical Investigator at Northwestern University Medical School, where he completed his postdoctoral training in Tumor Cell Biology and made his breakthrough discovery of Labyrinthin. This is also where he established his expertise in immune recognition, immune response, and various molecular approaches in understanding the physiology, morphology, and cell biology of human cancer. Dr. Radosevich has published five books and has over 400 published scientific papers, as well as 12 patents. He earned his Ph.D. in Experimental Pathology from the University of Illinois, Chicago.
Kenny W. Chan
Chairman of the Board
& Angel Investor
Mr. Chan is Chairman and Managing Director of Sun Ray Capital and its venture capital investing activities. Prior to co-founding LabyRx, he was involved in the successful discovery, development, and commercialization of several portfolio investments in the climate change, gold mining, and natural resources industries. Over the past 37 years, he has sourced, identified, and advised over 100 companies across diverse technology platforms. Previously, he was Founder and Chief Executive Officer at Enviro Energy International Holdings Ltd., and the lead financier at Pegasus Gold Corp. and Galactic Resources Ltd. While active in guiding portfolio companies, he also served as a member of the Board for several healthcare and technology companies. Mr. Chan started his career as an Investment Professional at Canaccord Genuity (formerly, Canarim Investment Corp.) and Yorkton Securities Inc. (which was later acquired by Macquarie).
David H. Voon, J.D.
Oski Capital Group, LabyRx Vice Chairman of the Board
Mr. Voon joined LabyRx in 2018 and is the Vice Chairman of the Board of Directors and an Angel Investor of the company. He has over 20 years of experience in finance and leading high-performing teams of professionals. His versatile career has included operational roles within securities law and derivatives structuring. He also held leadership positions covering equities, fixed income, and investment management. Prior to LabyRx, Mr. Voon worked at Goldman Sachs for 18 years, where he became Managing Director in 2001 and Partner in 2004. He also served as Head of Asia Private Wealth, a member of the Asia Management Committee, and the Investment Management Division's Global Operating Committee at Goldman Sachs (NYSE:GS). Along with two other former Goldman Sachs partners, he co-founded Oski Capital Partners in 2015. He earned his J.D. from Harvard Law School and received his Bachelor of Arts degree in Economics from the University of California, Berkeley.
Abbas Vafai, Ph.D.
Shingrix™, Viro Research, Scientific Advisor
Dr. Vafai is the microbiologist who discovered and developed the recombinant subunit shingles vaccine, Shingrix™, which is FDA-approved and marketed by GlaxoSmithKline in 2017. He is currently serving as Co-founder and Senior Scientific Advisor of Viro Research, where he most recently developed ZosterGent™, a new virus detection test for chickenpox and herpes zoster or shingles virus. Previously, Dr. Vafai has held senior positions within the health science industry, including, Branch Chief of Biologics and Associate Director at the Centers for Disease Control and Prevention. He has also held numerous academic appointments, including Professor of Neurology and Microbiology at the University of Colorado Health Sciences Center, and later at the University of Illinois College of Medicine, Rockford. Dr. Vafai earned his Ph.D. from Southern Illinois University and completed his postdoctoral fellowship in neurovirology at the University of Pennsylvania.
Inchul Lee, M.D., Ph.D.
Asan Medical Center,
Dr. Lee is a Principal Investigator, Professor, and founding member of Asan Medical Center, which has been a pioneer of precision medicine, cancer treatment, and the most well-respected medical institution in Korea for the past 14 years. Currently, he serves as a member of the Special Program Committee and a Professor of the Department of Pathology at Asan Medical Center (AMC) and the University of Ulsan College of Medicine, Seoul (UUCM). He also serves as a member of the American Association for Cancer Research. Prior to AMC and UUCM, he was an Assistant Professor of Pathology and Surgery at Rush Medical Center and a Visiting Professor at the German Cancer Research Center (DKFZ). Dr. Lee completed his clinical residency in Anatomic Pathology at Rush Presbyterian St. Luke’s Medical Center and has over two hundred published scientific papers. He earned his Ph.D. in Pathology from Kansai Medical University and his M.D. from Seoul National University College of Medicine.
Gabor Tarjan, M.D.
John H. Stroger Hospital, Scientific Advisor
Dr. Tarjan is a Cytopathology specialist focused on Anatomic and Clinical Pathology at John H. Stroger Jr. Hospital in Chicago, Illinois. He brings nearly 40 years of experience in medical healthcare research, pathology, and the diagnosis and non-surgical treatment of diseases in adults. Previously, he was a Clinical Associate Professor of Pathology at the University of Illinois, Chicago, where he was responsible for curriculum development and training the future generation of Pathologists. Dr. Tarjan completed both his postdoctoral fellowship and clinical residency at the McGaw Medical Center of Northwestern University and received his M.D. degree from Semmelweis University. He has published ten scientific papers on thyroid disorders, bone metabolism, and tumor biology.
Ming Yam Wong
Innolink Investments Ltd., Strategic Advisor
Mr. Wong is a veteran in industrial innovation and technology leadership, with over 35 years of experience in business operations and technology management. He currently serves as the Founding Director and Chairman of InnoLink Investments Ltd., where he is focused on investing in companies within the Green Technology and Bio-Health Technology industries. He also serves as Director and Board Member of multiple technology companies in Asia. Previously, Mr. Wong served as Board Chairman of Hong Kong Applied Science and Technology Research Institute (ASTRI), Honorary Chairman of Hong Kong Electronics & Technologies Association, Former Council Member and Deputy Chairman of Hong Kong Productivity Council, Director of Hong Kong Science & Technology Parks Corporation, and a member of the Innovation and Technology of Hong Kong Trade Development Council and Fund Vetting Committee. He has been the recipient of both the Silver Bauhinia Star (SBS), and the Bronze Bauhinia Star (BBS).